https://www.selleckchem.com/pr....oducts/Rapamycin.htm
Apatinib treatment was associated with longer survival times than supportive care for patients with sorafenib-resistant advanced HCC (median OS 7.0 4.0 months, 0.001). The results of the multivariate analysis demonstrated that liver tumor load [hazard ratio (HR) 3.653, 95% CI 2.047, 5.965, 0.001] and extrahepatic spread (HR 0.303, 95% CI 0.231, 0.778, = 0.003) were independent predictors of OS after apatinib treatment. This study showed that subsequent apatinib treatment may improve survival outcomes compared with support
Beğen
Yorum Yap
Paylaş
